EuroBiotech: More Articles of Note

Newspapers
(NS Newsflash/CC BY 2.0)

> DBV Technologies priced a $150 million (€121 million) stock offering. The round precedes a planned submission for approval of a peanut allergy therapy in the U.S. Statement

> Motif Bio delayed a filing for approval of its antibiotic, iclaprim. The biotech now plans to submit an application to the FDA in the second quarter. Release

>  Bavarian Nordic entered into a collaboration with the U.S. Department of Defense to develop a vaccine against the equine encephalitis virus. The deal is worth up to $36 million (€29 million). Statement

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> Shield Therapeutics outlined the analyses it presented to the FDA at a pre-NDA meeting. The pivotal trial missed its hematology-focused primary endpoint, but Shield thinks the result was affected by confounding data. Shield is now waiting to learn the FDA’s take. Release

> Arix Bioscience raised £87 million ($123 million) from new and existing investors. The financing will enable Arix to add to the 13 investments it has made so far. Statement

> Deinove secured an option on Redx Pharma’s bacterial topoisomerase inhibitor program. The deal gives Deinove nine months to evaluate the program before deciding whether to pay a fee to exercise its option. Release

Suggested Articles

The trial hit its primary endpoint by the time of an interim analysis, enabling Chi-Med to stop the study and start work on a filing for approval.

The anticipated fundraising haul will bankroll development of a pipeline of RAS programs up to the completion of IND-enabling studies.

As GlaxoSmithKline looks to start a 23andMe-partnered test this year, the Big Pharma is increasingly looking to tech for its R&D.